's stock had its "sell (d-)" rating reissued by analysts at
Weiss Ratings in a research report issued on Wednesday,
Weiss Ratings reports.
Tiziana Life Sciences Trading Up 5.5%
NASDAQ TLSA traded up $0.12 during trading hours on Wednesday, reaching $2.29. 715,787 shares of the company traded hands, compared to its average volume of 452,720. Tiziana Life Sciences has a 12 month low of $0.63 and a 12 month high of $2.60. The company has a 50 day moving average of $1.96 and a two-hundred day moving average of $1.58.
Hedge Funds Weigh In On Tiziana Life Sciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new position in shares of Tiziana Life Sciences during the 1st quarter valued at about $25,000. Marshall Wace LLP bought a new position in shares of Tiziana Life Sciences in the second quarter valued at approximately $39,000. Bison Wealth LLC bought a new position in shares of Tiziana Life Sciences in the fourth quarter valued at approximately $30,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Tiziana Life Sciences in the first quarter worth $156,000. Finally, Jane Street Group LLC grew its stake in shares of Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after acquiring an additional 151,858 shares during the last quarter.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
